Artificial Intelligence Better Than Risk Factors for Predicting Cancer Risk

Findings seen for screening - detected breast cancer, but not interval cancer risk
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Radiology, Journal, Source Type: news

Related Links:

AI tool could become part of diagnostic protocol More at https://www.nsf.gov/discoveries/disc_summ.jsp?cntn_id=303695&WT.mc_id=USNSF_1 This is a Research News item.
Source: NSF Discoveries - Category: Science Source Type: research
AbstractObjectivesTo compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients.Material and methodsA cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemarχ2 test was performed to compare sensitivity and specif...
Source: European Radiology - Category: Radiology Source Type: research
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Neurology, Oncology, Radiology, News, Source Type: news
Scientists are reporting a first: They used an advanced ultrasound technique to help deliver the drug Herceptin to the patients' brain tumors.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Metastatic Triple-Negative Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8 Intervention:   Biological: Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Intervention:   Drug: AC682 Sponsor:   Accutar Biotechnology Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
J Oncol. 2021 Oct 8;2021:9657071. doi: 10.1155/2021/9657071. eCollection 2021.ABSTRACTBreast cancer is a heterogeneous disease in which genetic factors are involved in disease worsening and higher mortality. Epidemiological and clinical research revealed that breast cancer incidence continues to rise. 100 histopathologically confirmed untreated newly diagnosed cases of invasive ductal carcinoma (IDC) of breast and 100 healthy subjects were involved and blood samples were collected in non-EDTA plain vials. Serum was separated by centrifugation, total RNA was extracted from serum, and cDNA synthesis was done to study the miR...
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: miR-520b inhibited PTEN and aggravated breast tumors. miR-520b inhibitor enhanced CD4 and CD8 cell populations in the tumor immune microenvironment and inhibited tumor growth.PMID:34659411 | PMC:PMC8514911 | DOI:10.1155/2021/5170496
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
Bull Cancer. 2021 Oct 14:S0007-4551(21)00365-9. doi: 10.1016/j.bulcan.2021.07.006. Online ahead of print.ABSTRACTINTRODUCTION: Episode-based bundled payment model is actually opposing to fee-for-service model, intending to incentivize coordinated care. The aims of these study were to determine episode-based costs for surgery in early breast cancer patients and to propose a payment model.METHODS: OPTISOINS01 was a multicenter prospective study including early breast cancer patients from diagnosis to one-year follow up. Direct medical costs, quality and patient reported outcomes were collected.RESULTS: Data from 604 patients...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research
Bull Cancer. 2021 Oct 14:S0007-4551(21)00368-4. doi: 10.1016/j.bulcan.2021.07.009. Online ahead of print.ABSTRACTA significant increase in breast cancer is expected in the coming decades among people with disabilities. However, their participation rate in screening programs is significantly lower than women without disabilities. Our objective was therefore to analyse the barriers to breast cancer screening in people with disabilities based on a recent review of the international literature. The articles analysed were retrieved from the PUBMED database from 2014 to 2020 using the following keywords "breast cancer"...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Radiology